Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat and Guadecitabine or ASTX727 in Unresectable and Metastatic Conventional Chondrosarcoma
NCT04340843Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Feb 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of belinostat, guadecitabine, inqovi in chondrosarcoma, sponsored by National Cancer Institute. Started Sep 2020; status: active, not recruiting.
02
Drugs
belinostatguadecitabineinqovi
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT04340843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340843.